前列腺癌患者[177Lu]Lu-PSMA靶向放射性药物治疗的剂量学:比较性系统综述与Meta分析
该系统综述与Meta分析纳入29篇文献共535例前列腺癌患者,比较[177Lu]Lu-PSMA-617与[177Lu]Lu-PSMA-I&T等放射性药物的器官和肿瘤吸收剂量。结果显示两者吸收剂量无显著差异,[177Lu]Lu-PSMA-I&T肾脏剂量可能偏高、[177Lu]Lu-PSMA-617肿瘤病灶剂量可能偏高,但各研究剂量学方法异质性显著,需标准化。
要点
- Meta分析纳入29篇文献535例患者,比较[177Lu]Lu-PSMA-617与[177Lu]Lu-PSMA-I&T的剂量学。
- 两者吸收剂量无显著差异,[177Lu]Lu-PSMA-I&T肾脏剂量可能偏高,[177Lu]Lu-PSMA-617肿瘤病灶剂量可能偏高。
- 各研究剂量学方法异质性显著,强调需要标准化。
核心结论
- Meta分析显示[177Lu]Lu-PSMA-I&T与[177Lu]Lu-PSMA-617的吸收剂量无显著差异。
- [177Lu]Lu-PSMA-I&T肾脏剂量可能偏高、[177Lu]Lu-PSMA-617肿瘤病灶剂量可能偏高,但该发现是否有临床影响尚不清楚。
- 各研究剂量学方法异质性显著,强调需要标准化。
研究设计与样本
- 系统综述与Meta分析,纳入29篇已发表文献共535例前列腺癌患者,比较[177Lu]Lu-PSMA-617、[177Lu]Lu-PSMA-I&T和[177Lu]Lu-J591的剂量学。
- 从纳入文献提取肾脏、腮腺、下颌下腺、骨髓、肝脏、泪腺及肿瘤病灶(骨与非骨病灶)的吸收剂量(Gy/GBq)。
- 将汇总平均吸收剂量按VISION试验(7.4 GBq)、SPLASH试验(6.8 GBq)和PROSTACT试验(5.8 GBq)的每周期注射活度归一化为Gy/周期。
主要发现
- [177Lu]Lu-PSMA-617与[177Lu]Lu-PSMA-I&T肾脏剂量分别为4.04 Gy/GBq(17项研究,297例)和4.70 Gy/GBq(10项研究,153例),P=0.10。
- 腮腺剂量分别为5.85 Gy/GBq(14项研究,216例)和2.62 Gy/GBq(5项研究,86例),P<0.01。
- 下颌下腺剂量分别为5.15 Gy/GBq(5项研究,81例)和4.35 Gy/GBq(1项研究,18例),P=0.56;泪腺剂量分别为11.03 Gy/GBq(6项研究,121例)和19.23 Gy/GBq(3项研究,53例),P=0.20。
- 骨髓剂量分别为0.24 Gy/GBq(12项研究,183例)和0.19 Gy/GBq(4项研究,68例),P=0.31;肝脏剂量分别为1.11 Gy/GBq(9项研究,154例)和0.56 Gy/GBq(4项研究,56例),P=0.05。
- 软组织肿瘤病灶平均剂量[177Lu]Lu-PSMA-617为4.19 Gy/GBq vs [177Lu]Lu-PSMA-I&T为2.94 Gy/GBq,P=0.26;[177Lu]Lu-J591剂量学数据仅限1项35例研究,肾脏、骨髓和肝脏吸收剂量分别为1.41、0.32和2.10 Gy/GBq。
关键数值与推荐
- [177Lu]Lu-PSMA-617与[177Lu]Lu-PSMA-I&T肾脏吸收剂量分别为4.04 Gy/GBq(17项研究,297例)和4.70 Gy/GBq(10项研究,153例),P=0.10。
- 腮腺吸收剂量分别为5.85 Gy/GBq(14项研究,216例)和2.62 Gy/GBq(5项研究,86例),P<0.01。
- 下颌下腺吸收剂量分别为5.15 Gy/GBq(5项研究,81例)和4.35 Gy/GBq(1项研究,18例),P=0.56;泪腺吸收剂量分别为11.03 Gy/GBq(6项研究,121例)和19.23 Gy/GBq(3项研究,53例),P=0.20。
- 骨髓吸收剂量分别为0.24 Gy/GBq(12项研究,183例)和0.19 Gy/GBq(4项研究,68例),P=0.31;肝脏吸收剂量分别为1.11 Gy/GBq(9项研究,154例)和0.56 Gy/GBq(4项研究,56例),P=0.05。
- 软组织肿瘤病灶平均剂量[177Lu]Lu-PSMA-617为4.19 Gy/GBq vs [177Lu]Lu-PSMA-I&T为2.94 Gy/GBq,P=0.26;[177Lu]Lu-J591肾脏、骨髓和肝脏吸收剂量分别为1.41、0.32和2.10 Gy/GBq(1项研究,35例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 各研究剂量学方法异质性显著,强调需要标准化。
- [177Lu]Lu-J591剂量学数据仅限1项已发表研究共35例患者。
- [177Lu]Lu-PSMA-I&T与[177Lu]Lu-PSMA-617肾脏和肿瘤病灶剂量的可能趋势是否有临床影响尚不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel theranostic approaches using radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have emerged for treating metastatic castration-resistant prostate cancer. The physical properties and commercial availability of 177Lu make it one of the most used radionuclides for radiopharmaceutical therapy (RPT). In this literature review, we aimed at comparing the dosimetry of the most used [177Lu]Lu-PSMA RPT compounds. Methods: This was a systematic review and metaanalysis of [177Lu]Lu-PSMA RPT (617, I&T, and J591) dosimetry in patients with prostate cancer. Absorbed doses in Gy/GBq for each organ at risk (kidney, parotid and submandibular glands, bone marrow, liver, and lacrimal glands) and for tumor lesions (bone and nonbone lesions) were extracted from included articles. These were used to estimate the pooled average absorbed dose of each agent in Gy/GBq and in Gy/cycle, normalized to the injected activity (per cycle) used in the VISION (7.4 GBq), SPLASH (6.8 GBq), and PROSTACT trials (5.8 GBq). Results: Twenty-nine published articles comprising 535 patients were included in the metaanalysis. The pooled doses (weighted average across studies) of [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T were 4.04 Gy/GBq (17 studies, 297 patients) and 4.70 Gy/GBq (10 studies, 153 patients) for the kidney (P = 0.10), 5.85 Gy/GBq (14 studies, 216 patients) and 2.62 Gy/GBq (5 studies, 86 patients) for the parotids (P < 0.01), 5.15 Gy/GBq (5 studies, 81 patients) and 4.35 Gy/GBq (1 study, 18 patients) for the submandibular glands (P = 0.56), 11.03 Gy/GBq (6 studies, 121 patients) and 19.23 Gy/GBq (3 studies, 53 patients) for the lacrimal glands (P = 0.20), 0.24 Gy/GBq (12 studies, 183 patients) and 0.19 Gy/GBq (4 studies, 68 patients) for the bone marrow (P = 0.31), and 1.11 Gy/GBq (9 studies, 154 patients) and 0.56 Gy/GBq (4 studies, 56 patients) for the liver (P = 0.05), respectively. Average tumor doses tended to be higher for [177Lu]Lu-PSMA-617 than for [177Lu]Lu-PSMA-I&T in soft tissue tumor lesions (4.19 vs. 2.94 Gy/GBq; P = 0.26). Dosimetry data of [177Lu]Lu-J591 were limited to one published study of 35 patients with reported absorbed doses of 1.41, 0.32, and 2.10 Gy/GBq to the kidney, bone marrow, and liver, respectively. Conclusion: In this metaanalysis, there was no significant difference in absorbed dose between [177Lu]Lu-PSMA-I&T and [177Lu]Lu-PSMA-617. There was a possible trend toward a higher kidney dose with [177Lu]Lu-PSMA-I&T and a higher tumor lesion dose with [177Lu]Lu-PSMA-617. It remains unknown whether this finding has any clinical impact. The dosimetry methodologies were strikingly heterogeneous among studies, emphasizing the need for standardization.
引用
- Ells Z, Grogan TR, Czernin J, et al. Dosimetry of [177Lu]Lu-PSMA-Targeted Radiopharmaceutical Therapies in Patients with Prostate Cancer: A Comparative Systematic Review and Metaanalysis. J Nucl Med. 2024. PMID: 38960712. doi:10.2967/jnumed.124.267452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。